Survey: Digital tools, flexible participation and empathy are key drivers for patient engagement in clinical trials

Survey: Digital tools, flexible participation and empathy are key drivers for patient engagement in clinical trials


March 27, 2023

Munich, Monday, March 27, 2023 – Climedo and Trials24 have published the results of their global patient survey which was conducted among more than 120 participants. The objective was to better understand clinical trials from a patient’s point of view, including barriers to participation, expectations and how trials can be improved. 

Among the 124 respondents, around 30% had previous trial experience and 70% did not but would consider taking part in a trial in the future. Most came from Europe and North America. Almost all age groups (19 to 60+ years) were represented, and the majority (68%) of respondents were female. The most common therapeutic areas represented were oncology, immunology, cardiology, dermatology, pain as well as several rare diseases. The majority of patients had taken part in a Phase I (>20%), II (14%) or III (17%) trial, while Phase IV was slightly less common (8%).

Some of the key findings are highlighted below.

Patient access to clinical trials

On-site visits, communication and travel during trials

Openness towards digital technologies

A look at the future 

“This patient survey reveals three recurring themes: a favorable attitude towards digital technologies in trials, a desire for flexible participation from home or on-the-go and a critical need for empathy and sensitivity towards patients”, says Veronika Schweighart, Co-Founder and COO of Climedo. “For us, this indicates that the industry must shift towards more hybrid trial designs that leverage digital technologies to alleviate patient burden while maintaining human interaction to convey important information and listen to patient needs, e.g. in televisits. The fact that nearly half of the respondents have not used digital technologies in trials is surprising to us and suggests that sponsors and sites must meet patient expectations to optimize participation. Climedo stands ready to assist sponsors, CROs and sites in adopting hybrid clinical trial designs to improve outcomes and generate higher-quality data while saving valuable resources for all stakeholders. We look forward to discussing the results with our network.”

The full survey results can be downloaded here.

About Climedo

Climedo offers a digital platform for hybrid clinical trials and observational studies. The easy-to-use, modular and secure data management software solution includes electronic data collection (EDC), ePRO, eCOA and telemedicine. It enables pharmaceutical and medical device companies to more efficiently validate their post-market medical innovations and capture real-world data in decentralized environments. This accelerates studies, saves costs, and improves data flow and quality while promoting innovative study designs. By seamlessly connecting all stakeholders (industry partners, study sites, physicians and patients) in a cloud-based system, Climedo is revolutionizing clinical research and making studies more accessible and patient-centric. Learn more:

About Trials24
Trials24 supports pharmaceutical, biotech and medtech companies as well as CROs in accelerating patient recruitment for their clinical trials. Trials24 specialises in finding suitable patients who are not registered in the trial centres’ databases. Learn more: